Clinical trials: Allogenic Disease
Acute Lymphoblastic Leukemia, Hodgkin Disease
Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD
With increasing cure rates of childhood cancer there is growing recognition of late effects of treatments. However, there is a lack of non-invasive and child-friendly procedures that can indicate possible late damage.
- Conditions
- Acute Lymphoblastic Leukemia, Hodgkin Disease, Allogeneic Stem Cell Transplantation
- Trial name
- MinimALL (NCT06093334)
- Testing
- Low-field magnetic resonance imaging, Cardiopulmonary testing, Pulmonary testing
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Hematologic Neoplasms
Assistance Program for Outpatients Following an Allogeneic Hematopoietic Stem-cell Transplant
After the initial monitoring period during hospitalization and isolation, patients with recent transplants are regularly monitored in monthly consultations but are still fragile, immunosuppressed and undergoing many treatments.
- Trial name
- AMA-ALLO (NCT04323605)
- Testing
- Outpatient assistance program for transplant patients (AMA-ALLO) based on a "navigation" nurse
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Toulouse
Mesenchymal Stromal Cell, Systemic Sclerosis
Manufacturing of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells for Treatment of Severe Systemic Sclerosis
Mesenchymal stromal cells (MSC) are multipotent cells which carry immunomodulatory, pro-angiogenic and anti-fibrotic properties, that can target Systemic Sclerosis (SSc) pathogenesis and its clinical manifestations.
- Trial name
- Pre_MSC-AT-SSc (NCT05947682)
- Testing
- Adipose tissue harvesting
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ulcerative Colitis, Inflammatory Bowel Diseases
Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis
Protocol Summary Title: A Phase I study of ExoFlo, an ex vivo culture-expanded adult allogeneic bone marrow mesenchymal stem cell derived extracellular vesicle isolate product, for the treatment of medically refractory ulcerative…
- Trial name
- NCT05176366
- Testing
- ExoFlo
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Direct Biologics, LLC
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS
The goal of this clinical research study is to find the highest safe dose of Mylotarg that can be combined with chemotherapy in patients receiving allogeneic bone marrow transplantation.
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia
- Trial name
- NCT00038831
- Testing
- Mylotarg, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Ischemic Cardiomyopathy, Coronary Artery Bypass Surgery
Human Umbilical Cord Stroma MSC in Myocardial Infarction
The purpose of this phase 1/2 clinical trial is to evaluate the efficacy and safety of allogeneic human umbilical cordstroma derived multipotent stem cells (hUCS-MSCs) in myocardial infarction (MI).
- Trial name
- HUC-HEART (NCT02323477)
- Testing
- stem cell transplantation
- Where
- Turkey (Türkiye)
- Volunteers
- 46 people
- Sponsor
- Ankara University
Cerebral Palsy
A Study of UCB and MSCs in Children With CP: ACCeNT-CP
The main purpose of this study is to estimate change in motor function 12 months after treatment with a single dose of allogeneic umbilical cord blood (AlloCB) or repeated doses of umbilical cord tissue-derived mesenchymal…
- Trial name
- ACCeNT-CP (NCT03473301)
- Testing
- Infusion of allogeneic umbilical cord blood, Infusion of MSCs
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Joanne Kurtzberg, MD
Leukemia, Myeloid
High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML
The purpose of this study is to evaluate the safety and efficiency of high dose allogeneic mismatched hematopoietic stem cells infusions after normal chemotherapy in patients with relapsed/refractory acute myeloid leukemia（AML）.
- Trial name
- NCT03080922
- Testing
- hematopoietic stem cell
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Hematological Malignancies, Regulatory T Cell Depletion
Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells
The investigators have previously shown the absence of toxicity of Treg-depleted-DLI and the possibility to triggering alloreactivity (GVHD/GVT) in relapsing patients dealing with hematological malignancies who had never shown…
- Conditions
- Hematological Malignancies, Regulatory T Cell Depletion, Relapse
- Trial name
- DLI-Boost (NCT03236129)
- Testing
- T-reg depleted DLI, Standard DLI
- Where
- France
- Volunteers
- 52 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Peripheral T Cell Lymphoma
Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR)
This study is a multicenter, two-arm, prospective clinical trial, comprising two groups: the allogeneic hematopoietic stem cell transplantation group (Allo-HSCT) and the autologous hematopoietic stem cell transplantation group…
- Trial name
- T-START-PR (NCT07253129)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Allogenic stem cell transplant (ASCT)
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Acute Lymphoblastic Leukaemia
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than…
- Trial name
- NCT01949129
- Testing
- VP16, TBI, Thiotepa
- Where
- 119 sites in Argentina, Australia and 29 more
- Volunteers
- 1,800 people
- Sponsor
- St. Anna Kinderkrebsforschung
Premature Ovarian Insufficiency
Phase 1 Clinical Trial of CordSTEM-ST
This clinical study will evaluate the safety and tolerability of CordSTEM-ST after administering a single dose in patients with premature ovarian insufficiency (POI), as well as identify the maximum tolerated dose (MTD) and…
- Trial name
- CBT210-POI_P1 (NCT06578039)
- Testing
- umbilical cord-derived mesenchymal stem cell
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- CHABiotech CO., Ltd
Alzheimer Disease
Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease
A3D is a phase I/II clinical trial. The primary objective is to evaluate the safety of allogeneic adipose tissue derived-stem cells (AdMSC) administered by intravenous (IV) route in mild to moderate Alzheimer disease (AD) using a…
- Trial name
- A3D (NCT07367815)
- Testing
- CellREADY® drug product IV dose of 50 millions, CellREADY® drug product IV dose of 100 millions, cerebral RMI
- Where
- France
- Volunteers
- 9 people
- Sponsor
- University Hospital, Toulouse
Ulcerative Colitis
Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Active Ulcerative Colitis
Phase I-II Clinical Trial - Safety and efficacy of umbilical-cord-derived mesenchymal stem cell (UC-MSC) in patients with active ulcerative colitis，randomized, single blind, controlled prospective study.
- Trial name
- UCMSC-UC (NCT02442037)
- Testing
- UCMSC group, Control group(Normal saline)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Prostate Cancer
Biological Therapy in Treating Patients With Prostate Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells including natural killer cells to kill prostate cancer cells. Interferon gamma may interfere with the growth of the cancer cells.
- Trial name
- NCT00002637
- Testing
- aldesleukin, gene-modified tumor cell vaccine therapy, recombinant interferon gamma
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Myelodysplastic Syndromes
Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy, such as treosulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00253513
- Testing
- fludarabine, treosulfan, allogeneic blood or bone marrow transplantation
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- OHSU Knight Cancer Institute
AML, Recurrent
NK Cell Therapy Recurrent/Refractory Elderly AML
The aim of this investigation was to assess safety and efficacy of allogenic NK cells therapy for recurrent refractory elderly AML.
- Conditions
- AML, Recurrent, Refractory, Elderly
- Trial name
- NCT04599452
- Testing
- Allogeneic NK cell regimen group
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Second Hospital of Shandong University
Lung Diseases, Interstitial
Nebulized Human Amniotic Fluid in Patients With Interstitial Lung Disease
This is a Phase I, pilot clinical trial designed to evaluate the safety and exploratory efficacy of nebulized diluted amniotic fluid, Matrix (HAF-Matrix) in adults with interstitial lung disease (ILD).
- Trial name
- HAF ILD (NCT07372989)
- Testing
- Matrix
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Maule Stem Cell Research Institute, Inc.
Leukemia, Myeloid, Acute
Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT
The goal of this phase I/II clinical trial is to test in high-risk acute myeloid leukemia (AML) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT).
- Trial name
- NCT05682755
- Testing
- Chidamide
- Where
- China
- Volunteers
- 77 people
- Sponsor
- Sichuan University
Acute-graft-versus-host Disease
A Study Comparing Corticosteroids Alone Versus Corticosteroids and Extracorporal Photopheresis (ECP) as First-line Treatment of Standard II Acute Graft-versus-host Disease
Acute graft versus host-disease remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation.
- Trial name
- PCE-aGVHD (NCT03605940)
- Testing
- Methoxsalen + ECP device, Corticosteroids
- Volunteers
- 78 people
- Sponsor
- Central Hospital, Nancy, France